Syndax reports 12 Revuforj abstracts accepted for EHA

Syndax (SNDX) Pharmaceuticals highlighted the release of 12 Revuforj abstracts on the European Hematology Association website in advance of the EHA 2026 Congress, taking place June 11-14. “The breadth of data accepted for presentation at EHA underscores the strength of revumenib’s clinical profile, with activity observed across the acute leukemia treatment continuum in KMT2Ar, NPM1m, and NUP98r acute leukemias. Given the need for therapies that can reduce the risk of relapse after stem cell transplantation, we are excited for the presentation of new data from the post-transplant setting showing favorable outcomes with revumenib compared to historical data. We also look forward to sharing additional frontline and R/R combination data showing high rates of MRD negativity, transplant, and favorable tolerability, supporting physician decision making and our ongoing pivotal trials. Collectively, these new data highlight our scientific leadership in menin inhibition and bolster our confidence that we are positioned to transform the treatment paradigm for 50% or more of patients with AML,” said Nick Botwood, MBBS, Head of Research & Development and Chief Medical Officer at Syndax.